Genscript Biotech Corporation

Genscript Biotech Corporation

G51 · F · Healthcare / Biotechnology

3.40EUR-0.20 (-5.56%)

Price History

Full chart

Market Stats

Previous Close3.60
Open3.40
Day Range3.40 – 3.40
52-Week Range1.14 – 5.10
Volume0
Market Cap11.04B
P/E (TTM)0.00
Forward P/E94.34
EPS-0.26
Dividend Yield0.00%
Beta0.98
50-Day Avg3.42
200-Day Avg1.90

About

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Weihui Shao
  • Employees6.13K
  • HeadquartersDah Sing Financial Centre, Wan Chai, Hong Kong, Germany
  • Websitehttps://www.genscript.com

Leadership

  • Mr. Jiange MengExecutive Chairman · b. 1968
  • Ms. Weihui ShaoCEO & COO · b. 1980
  • Ms. Ye Wang M.S.Co-Founder, President & Executive Director · b. 1968
  • Dr. Fangliang Zhang EMBA, Ph.D.Co-Founder & Executive Director · b. 1965
  • Dr. Li Zhu Ph.D.Chief Strategy Officer & Executive Director · b. 1950
  • Mr. Jing ZhouChief Financial Officer · b. 1979
  • Dr. Kening Li J.D.General Counsel & Chief Compliance Officer
  • Ms. Aylin Kosova BilginChief Marketing & Corporate Communications Officer
  • Dr. Bhama ParimooHead of Global Diversity, Equity & Inclusion(DEI)
  • Mr. Ernest LeeHead of Sustainability

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue114.73M152.65M231.02M273.35M390.33M510.60M625.70M560.48M594.49M959.53M
Growth (%)-+33.04%+51.34%+18.33%+42.79%+30.81%+22.54%-10.42%+6.07%+61.40%
Cost of Revenue38.51M48.06M72.48M93.06M134.95M207.58M321.62M289.85M322.36M406.32M
Gross Profit76.23M104.59M158.54M180.29M255.38M303.02M304.08M270.63M272.13M553.20M
Gross Margin66.44%68.52%68.63%65.95%65.43%59.35%48.60%48.29%45.77%57.65%
Operating Expense49.80M60.73M149.83M303.67M447.89M651.73M731.84M230.44M249.41M291.07M
Operating Income26.43M43.86M8.71M-123.38M-192.51M-348.71M-427.76M40.18M22.71M262.13M
Operating Margin23.03%28.73%3.77%-45.14%-49.32%-68.29%-68.36%7.17%3.82%27.32%
EBITDA-45.52M35.69M-92.27M-276.47M-494.00M-354.17M248.67M-85.09M-379.20M
EBITDA Margin-29.82%15.45%-33.75%-70.83%-96.75%-56.60%44.37%-14.31%-39.52%
Net Income26.17M26.12M21.22M-96.91M-204.94M-347.87M-226.85M-95.48M2.96B-532.83M
Net Income Margin22.81%17.11%9.18%-35.45%-52.51%-68.13%-36.26%-17.03%498.22%-55.53%
R&D--74.08M186.02M263.40M358.40M390.10M52.70M53.79M71.23M
R&D as % of Total Revenue--32.07%68.05%67.48%70.19%62.35%9.40%9.05%7.42%
Interest Expense0052.00K781.00K1.42M2.38M13.27M5.74M8.03M17.29M
Interest Expense % of Total Revenue0.00%0.00%0.02%0.29%0.36%0.47%2.12%1.02%1.35%1.80%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets226.03M504.26M916.98M889.41M1.45B2.23B2.55B3.39B5.28B4.85B
Total Liabilities42.01M275.94M423.68M517.11M631.82M1.14B1.18B1.34B954.91M888.59M
Total Equity177.61M217.81M478.66M382.80M901.71M879.75M1.01B1.39B4.32B3.96B
Cash136.46M123.86M494.56M252.40M629.06M1.18B1.02B1.45B131.99M142.49M
Net Debt---------52.18M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow33.27M21.37M307.66M-29.95M-151.09M-136.79M-120.29M-286.91M75.65M325.52M
Investing Cash Flow-8.31M-36.45M-193.96M-208.63M-100.17M-212.55M----
Financing Cash Flow-2.04M257.32M-2.78M624.20M902.14M----
Capital Expenditure8.98M29.21M70.84M110.37M121.88M133.04M203.57M157.71M147.92M83.84M
Free Cash Flow--10.60M215.80M-148.49M-151.09M-136.79M-323.86M-444.62M-72.27M241.69M
Dividends Paid-2.63M--------
FCF to OCF--49.62%70.14%495.71%100.00%100.00%269.23%154.97%-95.54%74.25%
Dividend Paid to FCF--24.85%--------

Earnings

Report DateMar 15, 2027
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap11.04B
Enterprise Value10.12B
Trailing P/E0.00
Forward P/E94.34
Price / Sales13.06
Price / Book3.18
EPS-0.26
Book Value1.53
Revenue (TTM)844.97M
Gross Profit (TTM)439.28M
EBITDA192.65M
Profit Margin-75.35%
Operating Margin12.26%
Return on Equity-15.33%
Return on Assets1.54%
Shares Outstanding2.28B
Shares Float1.41B
Beta0.98
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20171×
0.00Jun 6, 2017